1. The Diabetic Retinopathy Clinical Research Network One-Year Results from a Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy Abdhish Bhavsar, MD for the Diabetic Retinopathy Clinical Research Network Supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services; EY14231 and EY018817 1

2. Financial Disclosures  Research Grant Support: DRCR, Genentech 2

3. Study Objectives  To determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed by 16 weeks compared with saline injections in eyes presenting with vitreous hemorrhage from PDR. Note: This trial was not a comparison of anti-VEGF with observation or sham injection; rather the trial was a comparison of intravitreal anti-VEGF with intravitreal saline injection  To assess the efficacy and safety through 16 weeks, and safety through 52 weeks, of anti-VEGF therapy as treatment for vitreous hemorrhage due to PDR. 3

4. Study Design, Enrollment, Follow-up  At least one eye that met all of the following criteria:  Vitreous hemorrhage causing vision impairment, presumed to be from PDR, and precluding completion of PRP  Immediate vitrectomy is not required  Visual acuity is light perception or better  No prior anti-VEGF treatment for VH Randomized, Multi-center,Double Masked Trial Primary Outcome: Treatment group comparison of the cumulative probabilities of vitrectomy by 16 weeks of randomization. 4

5. Study Enrollment 261 Eyes Randomized (61 Sites) 261 Eyes Randomized (61 Sites) 12 Week Visit Completion (primary outcome) = 95% Overall* (96% Ranibizumab Injection; 95% Saline Injection) 12 Week Visit Completion (primary outcome) = 95% Overall* (96% Ranibizumab Injection; 95% Saline Injection) Intravitreal Injection of 0.5 ranibizumab N = 125 Intravitreal Injection of 0.5 ranibizumab N = 125 Intravitreal Injection 0.9% sodium chloride N = 136 Intravitreal Injection 0.9% sodium chloride N = 136 * One death occurred prior to the 12 week visit and 5 deaths were reported between 12 to 52 weeks of study follow-up. 5 52 Week Visit Completion (additional safety outcomes) (80% Ranibizumab Injection; 83% Saline Injection) 52 Week Visit Completion (additional safety outcomes) (80% Ranibizumab Injection; 83% Saline Injection)

6. Follow-up Schedule Phase 1 Phase 2 4 WK VISIT 26 WK Phone Call 8 WK VISIT 12 WK VISIT 52 WK VISIT 6

7. Study Treatment  Follow-up injections performed at 4 and 8 weeks unless: Vitreous hemorrhage had cleared enough to complete PRP or Vitrectomy had been performed.  All eyes were to be treated with complete PRP as soon as possible.  Prior to the 16 week endpoint, the decision to perform vitrectomy was based on study guidelines.  Further treatment following the 16 week endpoint was at Investigator discretion.  PRP was to be initiated as soon as possible 7

8. Baseline Study Eye Characteristics 8 Ranibizumab N = 125 Saline N = 136 Prior PRP50%57% Prior Treatment for DME42% Prior treatment with anti-VEGF for DME8%13% E-ETDRS Visual Acuity letter score Median (25 th, 75 th Percentile); Snellen Equivalent 34 (0,61) 20/20028 (0,59) 20/320 Duration of Vitreous Hemorrhage <1 Month53%55% 1-3 Months33%29% 4-6 Months6%8% >6 Months9%8%

9. Non-Protocol Study Eye Treatment Post 16 weeks Ranibizumab Injection Saline Injection Number of Eyes with Non-Protocol Study Eye Treatment for DME 2032 Intravitreal Bevacizumab (Avastin)1525 Intravitreal Ranibizumab (Lucentis)05 Intravitreal Pegaptanib (Macugen) 20 Other: Unspecified Anti-VEGF01 Intravitreal Kenalog Injection01 Intravitreal Triamcinolone Acetonide20 Intravitreal Triesence10 9

10. Vitrectomy Primary Outcome 10

11. Cumulative Probability of Vitrectomy by 16 Weeks

12. Conclusions Primary Outcome  This study suggests little likelihood of a clinically important difference between ranibizumab and saline on the rate of vitrectomy by 16 weeks in eyes with VH from PDR.  As a result of having substantially overestimated the control group rate when estimating sample size, the study may not have been sufficiently powered to detect a treatment group difference. 12

13. Vitrectomy Secondary Outcome 13

14. 14 Cumulative Probability of Vitrectomy by 52 Weeks No follow-up contact was performed between 16 to 52 weeks

15. “Complete” Panretinal Photocoagulation Secondary Outcome 15

16. Cumulative Probability of “Complete” PRP (in absence of vitrectomy) by 16 Weeks

17. Cumulative Probability of “Complete” PRP (in absence of vitrectomy) by 52 Weeks 17 No follow-up contact was performed between 16 to 52 weeks.

18. Visual Acuity at Follow-up Visits Secondary Outcome 18

19. Mean Change in Visual Acuity from Baseline Prior to 16 Weeks † Treatment comparison for the mean change in visual acuity at the 12 week visit was performed using a longitudinal mixed model adjusting for baseline visual acuity. † P=0.04 19

20. Mean Change in Visual Acuity from Baseline – Up to 52 weeks No follow-up contact was performed between 16 weeks to 52 weeks. 20

21. Conclusions Secondary Outcomes  By 52 weeks, the rate of vitrectomy remained similar between the two treatment groups with over 1/3 of eyes in both groups undergoing vitrectomy.  Short term secondary outcomes including visual acuity improvement, increased PRP completion rates, and reduced recurrent VH rates suggest biologic activity of ranibizumab by 16 weeks of study follow-up. 21

22. Conclusions Secondary Outcomes  The ability to perform PRP appeared slightly better in the ranibizumab group throughout one-year of follow-up; however the improvement in mean visual acuity observed at 12 weeks was no longer present at 52 weeks.  It should be noted that treatment after the 16 week endpoint was at the investigator’s discretion. 22

23. Safety Outcomes 23

24. Ocular Adverse Events of Interest Ocular Events Ranibizumab Injection N = 125 Saline Injection N = 136 Recurrent Vitreous Hemorrhage Prior to 16 weeks ¥ 6%17% 16 weeks – 52 weeks13% Traction and/or Rhegmatogenous Retinal Detachment Prior to 16 weeks ¥ 8% 16 weeks – 52 weeks7%10% ¥ Treatment comparison for recurrent vitreous hemorrhage was performed using Fisher Exact test (P-value = 0.01) 24

25. Conclusions Safety Outcomes  Intravitreal ranibizumab does not appear to increase the risk of retinal detachment throughout one-year of study follow-up.  The evaluation of intravitreal saline versus ranibizumab given at baseline, 4 and 8 weeks after randomization in eyes with vitreous hemorrhage, showed no difference in safety between the two treatment groups at 52 weeks. 25

26. Discussion  Whether vitrectomy rates after saline or ranibizumab are different than observation alone cannot be determined from this study.  Further follow-up on these two groups indicate a relatively high incidence of vitrectomy in both groups by one year. 26